Litcius/Paper detail

Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)

Céline Boschi, Philippe Colson, Audrey Bancod, Valérie Moal, Bernard La Scola

2022Clinical Infectious Diseases30 citationsDOIOpen Access PDF

Abstract

International audience

Topics & Concepts

MedicineMonoclonal antibodyVirologyAntibodyImmunologyInhalation and Respiratory Drug DeliveryInnovative Microfluidic and Catalytic Techniques InnovationBiosimilars and Bioanalytical Methods
Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC) | Litcius